FDA approves 1st mRNA flu shot, from Moderna

The U.S. Food and Drug Administration (FDA) has approved Moderna’s influenza vaccine, marking the first licensed flu shot developed using messenger RNA (mRNA) technology. This approval signifies a significant advancement in flu vaccination methods, as mRNA technology has previously been utilized in COVID-19 vaccines but is now being applied to influenza. The vaccine, named mFlusiva, was demonstrated in clinical trials to be up to 27 percent more effective than traditional flu vaccines, according to Scientific American. The approval of the mRNA flu vaccine was reported by multiple news outlets, including NBC News, The Washington Post, Stat News, Reuters, and AP News. The FDA's decision is expected to pave the way for a new type of flu shot that could enhance the effectiveness of seasonal flu vaccinations. The mRNA technology allows for a more rapid response to evolving flu strains, which is a critical factor in managing seasonal influenza outbreaks. Moderna's mRNA flu vaccine represents a novel approach in the fight against influenza, potentially improving public health outcomes. The approval reflects ongoing advancements in vaccine technology and the increasing reliance on mRNA platforms for various infectious diseases. As the vaccine becomes available, it may change the landscape of flu prevention strategies in the United States and beyond.